Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.
Antonio Gonzáles MartinMaría Jesús RubioFlorian HeitzRené Depont ChristensenNicoletta ColomboToon Van GorpMargarita Romeo MarinIsabelle L Ray-CoquardLydia GabaAlexandra LearyLuis Miguel De SandeCoriolan LebretonAndrés RedondoMichel FabbroMaria-Pilar Barretina GinestaPhilippe FollanaJosé Alejandro Pérez-FidalgoManuel J RodriguesAna SantaballaRenaud SabatierMaria José Bermejo-PérezJean-Pierre LotzBeatriz PardoGloria MarquinaLuisa Sanchez LorenzoMaría QuindósPurificación Estévez-GarcíaEva Guerra AlíaLuis Manso SanchezVictoria CasadoStefan KommossGermana TognonStéphanie HenryIlan BruchimAna OakninFrédéric SellePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Combining atezolizumab with CT and maintenance niraparib for late-relapsing recurrent ovarian cancer did not significantly improve PFS or the ORR.
Keyphrases